Literature DB >> 3665673

Solid tumor preparation for clinical application of flow cytometry.

J F Ensley1, Z Maciorowski, H Pietraszkiewicz, M Hassan, J Kish, M Al-Sarraf, J Jacobs, A Weaver, D Atkinson, J Crissman.   

Abstract

Intense interest in advanced squamous cell cancers of the head and neck (SCC of H&N) has resulted from the recent progress made in tumor responses with chemotherapy and radiotherapy. Unfortunately, the response patterns and clinical outcome of such patients are not adequately predicted on an individual patient basis using clinical parameters or conventional morphology. The study of flow cytometrically determined cellular parameters in such tumors is therefore of interest, but is hindered by inadequate tumor preparative technology. The previous article (10) in this journal describes the use of a murine SCC tumor, LC12, which was employed for comparative testing and determination of optimum techniques of preparation for this tumor. This report describes the application of these techniques to 144 specimens of human SCC of H&N. The mean total yield for these specimens is 7.4 X 10(7) cells/g of tissue. The mean viable enzymatic yield (3.3 X 10(7) cells/g) was higher than the mean viable mechanical yield (2.0 X 10(7) cells/g) except when lymph nodes were the source of the specimen (5.4 X 10(7) cells/g). The mean dye exclusion viability from enzymatically dissociated specimens were above 90%. Significant aneuploidal subpopulation losses were evident in mechanically dissociated and enucleated specimens. 65% of the enzymatically dissociated specimens were successfully cultured with a mean cloning efficiency of 2.1 X 10(-3). Preparative techniques derived from comparative testing with a murine standard tumor have been successfully applied to 144 specimens of SCC of H&N with resultant high yields and excellent viability. Technical problems detected during the preliminary testing with LC12 were confirmed in the human tumors.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3665673     DOI: 10.1002/cyto.990080509

Source DB:  PubMed          Journal:  Cytometry        ISSN: 0196-4763


  6 in total

1.  Tissue preparation for simultaneous flow cytometric quantitation of tumour associated antigens and DNA in solid tumours.

Authors:  P A van Dam; J V Watson; D G Lowe; H Cox; M Curling; J H Shepherd
Journal:  J Clin Pathol       Date:  1990-10       Impact factor: 3.411

2.  Cellular DNA content parameters as prognostic indicators in human astrocytomas.

Authors:  Basil F El-Rayes; Camille S Norton; Wael Sakr; Zosia Maciorowski; Daryn Smith; Haline Pietraszkiewicz; Maria Del Mar Alonso; John F Ensley
Journal:  J Neurooncol       Date:  2005-01       Impact factor: 4.130

Review 3.  The clinical application of DNA content and kinetic parameters in the treatment of patients with squamous cell carcinomas of the head and neck.

Authors:  J F Ensley
Journal:  Cancer Metastasis Rev       Date:  1996-03       Impact factor: 9.264

4.  Radioluminescence microscopy: measuring the heterogeneous uptake of radiotracers in single living cells.

Authors:  Guillem Pratx; Kai Chen; Conroy Sun; Lynn Martin; Colin M Carpenter; Peter D Olcott; Lei Xing
Journal:  PLoS One       Date:  2012-10-03       Impact factor: 3.240

5.  Prognostic value of clinicopathological parameters in head and neck squamous cell carcinoma: a prospective analysis.

Authors:  F Janot; J Klijanienko; A Russo; J P Mamet; F de Braud; A K El-Naggar; J P Pignon; B Luboinski; E Cvitkovic
Journal:  Br J Cancer       Date:  1996-02       Impact factor: 7.640

6.  Contribution of multiparameter flow cytometry immunophenotyping to the diagnostic screening and classification of pediatric cancer.

Authors:  Cristiane S Ferreira-Facio; Cristiane Milito; Vitor Botafogo; Marcela Fontana; Leandro S Thiago; Elen Oliveira; Ariovaldo S da Rocha-Filho; Fernando Werneck; Danielle N Forny; Samuel Dekermacher; Ana Paula de Azambuja; Sima Esther Ferman; Paulo Antônio Silvestre de Faria; Marcelo G P Land; Alberto Orfao; Elaine S Costa
Journal:  PLoS One       Date:  2013-03-05       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.